Prosight Management LP Has $3.31 Million Holdings in Sight Sciences, Inc. (NASDAQ:SGHT)

Prosight Management LP increased its position in shares of Sight Sciences, Inc. (NASDAQ:SGHT - Free Report) by 71.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 908,847 shares of the company's stock after buying an additional 377,625 shares during the period. Sight Sciences accounts for 0.9% of Prosight Management LP's holdings, making the stock its 25th biggest position. Prosight Management LP owned about 1.79% of Sight Sciences worth $3,308,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of SGHT. Dynamic Technology Lab Private Ltd purchased a new position in Sight Sciences in the 4th quarter valued at about $40,000. Arkadios Wealth Advisors purchased a new stake in Sight Sciences in the 4th quarter valued at about $47,000. WealthTrust Asset Management LLC acquired a new position in shares of Sight Sciences in the 4th quarter worth approximately $48,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Sight Sciences in the fourth quarter valued at $50,000. Finally, Stoneridge Investment Partners LLC acquired a new position in Sight Sciences in the 4th quarter valued at about $55,000. Hedge funds and other institutional investors own 55.51% of the company's stock.

Insider Transactions at Sight Sciences

In other news, CEO Paul Badawi sold 24,174 shares of the business's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $2.30, for a total transaction of $55,600.20. Following the completion of the sale, the chief executive officer now owns 6,010,580 shares in the company, valued at approximately $13,824,334. The trade was a 0.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Manohar K. Raheja purchased 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was acquired at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the acquisition, the executive vice president now directly owns 145,000 shares of the company's stock, valued at $395,850. This trade represents a 7.41% increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 35,196 shares of company stock worth $81,001 in the last ninety days. Insiders own 30.90% of the company's stock.

Sight Sciences Trading Up 0.5%

NASDAQ SGHT traded up $0.02 during trading hours on Tuesday, hitting $3.29. 66,123 shares of the company's stock were exchanged, compared to its average volume of 213,911. The business's 50 day moving average is $2.78 and its 200-day moving average is $3.14. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. Sight Sciences, Inc. has a 12-month low of $2.03 and a 12-month high of $8.45. The firm has a market capitalization of $169.82 million, a P/E ratio of -3.22 and a beta of 2.41.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The business had revenue of $17.51 million for the quarter, compared to analyst estimates of $16.51 million. As a group, analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on SGHT. Stifel Nicolaus reduced their price objective on Sight Sciences from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Piper Sandler cut their price target on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a research report on Thursday, March 6th. Lake Street Capital raised their price target on Sight Sciences from $2.50 to $3.00 and gave the stock a "hold" rating in a report on Friday, May 9th. Citigroup reduced their target price on shares of Sight Sciences from $4.60 to $3.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Finally, UBS Group lowered their price target on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Sight Sciences presently has an average rating of "Hold" and an average price target of $3.92.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.